Form D · Pharmaceuticals
Oxygen Therapy, Inc.
Newton, MA · CIK 0001685616
Offering snapshot reported Jun 16, 2017 · SEC filing
- Reported sold
- $240K Offering amount: $240K
- Investors reported
- 10 Form D · investor count
- Minimum accepted
- $10K Reported outside-investor minimum
- First sale
- Jun 6, 2016 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 16, 2017 | Initial | $240,000 | No comparison | 10 | SEC filing |
| Sep 27, 2016 | Initial | $300,000 | No comparison | 12 | SEC filing |
Offering details
- Securities
- Debt
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-288953
Source: Form D, filed Jun 16, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Dale H. Conaway | Director |
| Henry J. Esber | Director |
| Alan Hoberman | Director |
| Yuval Kwintner | Director, Executive |
| David Platt | Director, Executive |
| Ola Soderquist | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
233 Needham Street Suite 300
Newton, MA, 02464
Newton, MA, 02464